PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2407

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma ; volume:21 ; number:1 ; day:23 ; month:3 ; year:2021 ; pages:1-9 ; date:12.2021
BMC cancer ; 21, Heft 1 (23.3.2021), 1-9, 12.2021

Creator: Pinato, David J.
Cortellini, Alessio
Sukumaran, Ajithkumar
Cole, Tom
Pai, Madhava
Habib, Nagy
Spalding, Duncan
Sodergren, Mikael H.
Martinez, Maria
Dhillon, Tony
Tait, Paul
Thomas, Robert
Ward, Caroline
Kocher, Hemant
Yip, Vincent
Slater, Sarah
Sharma, Rohini

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12885-021-08033-x

URN: urn:nbn:de:101:1-2021050808582338752819

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:54 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Pinato, David J.
Cortellini, Alessio
Sukumaran, Ajithkumar
Cole, Tom
Pai, Madhava
Habib, Nagy
Spalding, Duncan
Sodergren, Mikael H.
Martinez, Maria
Dhillon, Tony
Tait, Paul
Thomas, Robert
Ward, Caroline
Kocher, Hemant
Yip, Vincent
Slater, Sarah
Sharma, Rohini
SpringerLink (Online service)

Other Objects (12)

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab

Related objects

Reset password